| Role of B cells as antigen presenting cells I Rastogi, D Jeon, JE Moseman, A Muralidhar, HK Potluri, DG McNeel Frontiers in immunology 13, 954936, 2022 | 77 | 2022 |
| Treatment combinations with DNA vaccines for the treatment of metastatic castration-resistant prostate cancer (mCRPC) M Gamat-Huber, D Jeon, LE Johnson, JE Moseman, A Muralidhar, ... Cancers 12 (10), 2831, 2020 | 17 | 2020 |
| Vaccines as treatments for prostate cancer I Rastogi, A Muralidhar, DG McNeel Nature Reviews Urology 20 (9), 544-559, 2023 | 16 | 2023 |
| Targeted Radiation and Immune Therapies—Advances and Opportunities for the Treatment of Prostate Cancer A Muralidhar, HK Potluri, T Jaiswal, DG McNeel Pharmaceutics 15 (1), 252, 2023 | 5 | 2023 |
| Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacy A Muralidhar, M Gamat-Huber, S Vakkalanka, DG McNeel Journal for Immunotherapy of Cancer 12 (5), 2024 | | 2024 |
| Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using 90Y-NM600 in combination with androgen deprivation therapy in murine … A Muralidhar, R Hernandez, ZS Morris, HC Rojas, MB Idrissou, ... Journal for Immunotherapy of Cancer 12 (4), 2024 | | 2024 |
| 882 Timing and sequencing of AR-specific vaccination combined with androgen deprivation therapy affect anti-tumor responses in murine prostate cancer models A Muralidhar, D McNeel Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 893 Myeloid derived suppressive cells attenuate the anti-tumor efficacy of androgen deprivation therapy and targeted radionuclide therapy in a murine prostate cancer model A Muralidhar, C Ferreria, R Hernandez, J Weichert J Immunother 10 (2), A1-A1595, 2022 | | 2022 |
